Adults with unresectable/metastatic melanoma who failed ipilimumab +/- anti-PD1, and ECOG PS 0–1 were randomized to one of three dose groups: low (0.3mg/kg), intermediate (1.0mg/kg), and high (dose escalation: 3+3 design 1.8–3.6mg/kg, dose-expansion at MTD or 3.6mg/kg). The gene discussed is PDCD1; the disease is metastatic melanoma.